We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...

Abbott (ABT) announced that the U.S. Food and Drug Administration, FDA, has approved an investigational device exemption, IDE, for its Coronary ...

Abbott Laboratories closed 11.07% short of its 52-week high of $141.23, which the company achieved on March 4th.

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Abbott Laboratories (NYSE:ABT) has caught investor attention with the FDA’s approval of an Investigational Device Exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System, a significant ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...

The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

Abbott Laboratories and Reckitt Benckiser Group Plc shares fell as a judge ordered a new trial after rejecting a verdict that ...

Abbott Laboratories closed 10.57% short of its 52-week high of $141.23, which the company reached on March 4th.